Pharmacological inhibition of protein kinase CK2 reverts the multidrug resistance phenotype of a CEM cell line characterized by high CK2 level

Oncogene

Volumn 26, Issue 48, 2007, Pages 6915-6926

  Di Maira, G ^a,b   Brustolon, F ^a,b   Bertacchini, J ^c   Tosoni, K ^a,b   Marmiroli, S ^c   Pinna, L A ^a,b   Ruzzene, M ^a,b  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETIAN INSTITUTE OF MOLECULAR MEDICINE   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Casein kinase 2; CEM cells; CK2; CKII; Inhibitors; MDR

Indexed keywords

1,8 DIHYDROXY 4 NITROANTHRACENE 9,10 DIONE; 2 AMINO 4,5,6,7 TETRABROMO 1H BENZIMIDAZOLE; 4,5,6,7 TETRABROMOBENZIMIDAZOLE; 4,5,6,7 TETRABROMOBENZOTRIAZOLE; ANTINEOPLASTIC AGENT; CASEIN KINASE II; DOXORUBICIN; ENZYME INHIBITOR; ETOPOSIDE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VINBLASTINE;

ALPHA CHAIN; APOPTOSIS; ARTICLE; BETA CHAIN; CELL DEATH; CELL TYPE; CELL VIABILITY; CHEMOSENSITIVITY; CHEMOSENSITIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; DRUG UPTAKE; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IC 50; LYMPHOBLASTOID CELL LINE; MULTIDRUG RESISTANCE; OSTEOSARCOMA CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOTTING, WESTERN; BONE NEOPLASMS; CASEIN KINASE II; CELL SURVIVAL; CELLS, CULTURED; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; OSTEOSARCOMA; PHOSPHORYLATION; RABBITS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; T-LYMPHOCYTES; TRANSFECTION; VINBLASTINE;

EID: 35349015771     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210495     Document Type: Article

References (37)

1. Ahmad KA, Harris NH, Johnson AD, Lindvall HC, Wang G, Ahmed K. (2007). Protein kinase CK2 modulates apoptosis induced by resveratrol and epigallocatechin-3-gallate in prostate cancer cells. Mol Cancer Ther 6: 1006-1012.
2. Ahmad KA, Wang G, Slaton J, Unger G, Ahmed K. (2005). Targeting CK2 for cancer therapy. Anticancer Drugs 16: 1037-1043.
3. Ahmed K, Gerber DA, Cochet C. (2002). Joining the cell survival squad: an emerging role for protein kinase CK2. Trends Cell Biol 12: 226-230.
4. Allende CC, Allende JE. (1998). Promiscuous subunit interactions: a possible mechanism for the regulation of protein kinase CK2. J Cell Biochem Suppl 30-31: 129-136.
5. Borst P. (1997). Multidrug resistant proteins. Semin Cancer Biol 8: 131-134.
6. Cenni V, Maraldi NM, Ruggeri A, Secchiero P, Del Coco R, De Pol A et al. (2004). Sensitization of multidrug resistant human ostesarcoma cells to Apo2 Ligand/TRAIL-induced apoptosis by inhibition of the Akt/PKB kinase. Int J Oncol 25: 1599-1608.
7. De Moliner E, Moro S, Sarno S, Zagotto G, Zanotti G, Pinna LA et al. (2003). Inhibition of protein kinase CK2 by anthraquinone-related compounds. A structural insight. J Biol Chem 278: 1831-1836.
8. Di Maira G, Salvi M, Arrigoni G, Marin O, Sarno S, Brustolon F et al. (2005). Protein kinase CK2 phosphorylates and upregulates Akt/PKB. Cell Death Differ 12: 668-677.
9. Dupuis ML, Tombesi M, Sabatini M, Cianfriglia M. (2003). Differential effect of HIV-1 protease inhibitors on P-glycoprotein function in multidrug-resistant variants of the human CD4+ T lymphoblastoid CEM cell line. Chemotherapy 49: 8-16.
10. Filhol O, Martiel JL, Cochet C. (2004). Protein kinase CK2: a new view of an old molecular complex. EMBO Rep 5: 351-355.
11. Giovannetti E, Mey V, Danesi R, Mosca I, Del Tacca M. (2004). Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines. Clin Cancer Res 10: 2936-2943.
12. Glavy JS, Horwitz SB, Orr GA. (1997). Identification of the in vivo phosphorylation sites for acidic-directed kinases in murine mdr1b P-glycoprotein. J Biol Chem 272: 5909-5914.
13. Guerra B, Issinger OG. (1999). Protein kinase CK2 and its role in cellular proliferation, development and pathology. Electrophoresis 20: 391-408.
14. Guo C, Yu S, Davis AT, Wang H, Green JE, Ahmed K. (2001). A potential role of nuclear matrix-associated protein kinase CK2 in protection against drug-induced apoptosis in cancer cells. J Biol Chem 276: 5992-5999.
15. Kelliher MA, Seldin DC, Leder P. (1996). Tal-1 induces T cell acute lymphoblastic leukemia accelerated by casein kinase IIalpha. EMBO J 15: 5160-5166.
16. Klumpp S, Maurer A, Zhu Y, Aichele D, Pinna LA, Krieglstein J. (2004). Protein kinase CK2 phosphorylates BAD at threonine-117. Neurochem Int. 45: 747-752.
17. Landesman-Bollag E, Channavajhala PL, Cardiff RD, Seldin DC. (1998). p53 deficiency and misexpression of protein kinase CK2alpha collaborate in the development of thymic lymphomas in mice. Oncogene 16: 2965-2974.
18. Ling V. (1997). Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother Pharmacol 40: S3-S8.
19. Litchfield DW. (2003). Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem J 369: 1-15.
20. Matsumoto Y, Takano H, Kunishio K, Nagao S, Fojo T. (2001). Expression of drug resistance genes in VP-16 and mAMSA-selected human carcinoma cells. Jpn J Cancer Res 92: 778-784.
21. Meggio F, Pinna LA. (2003). One-thousand-and-one substrates of protein kinase CK2? FASEB J 17: 349-368.
22. Meggio F, Pagano MA, Moro S, Zagotto G, Ruzzene M, Sarno S et al. (2004). Inhibition of protein kinase CK2 by condensed polyphenolic derivatives. An in vitro and in vivo study.. Biochemistry 43: 12931-12936.
23. Orlandini M, Semplici F, Ferruzzi R, Meggio F, Pinna LA, Oliviero S. (1998). Protein kinase CK2alpha′ is induced by serum as a delayed early gene and cooperates with Ha-ras in fibroblast transformation. J Biol Chem 273: 21291-21297.
24. Pagano MA, Andrzejewska M, Ruzzene M, Sarno S, Cesaro L, Bain J et al. (2004). Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem 47: 6239-6247.
25. Pinna LA. (1990). Casein kinase 2: an 'eminence grise' in cellular regulation? Biochim Biophys Acta 1054: 267-284.
26. Pinna LA. (2002). Protein kinase CK2: a challenge to canons. J Cell Sci 115: 3873-3878.
27. Ruzzene M, Penzo D, Pinna LA. (2002). Protein kinase CK2 inhibitor 4,5,6,7-tetrabromobenzotriazole (TBB) induces apoptosis and caspase-dependent degradation of haematopoietic lineage cell-specific protein 1 (HS1) in Jurkat cells. Biochem J 364: 41-47.
28. Salvi M, Sarno S, Marin O, Meggio F, Itarte E, Pinna LA. (2006). Discrimination between the activity of protein kinase CK2 holoenzyme and its catalytic subunits. FEBS Lett 580: 3948-3952.
29. Sarno S, de Moliner E, Ruzzene M, Pagano MA, Battistutta R, Bain J et al. (2003). Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a) quinazolin-7-yl]-acetic acid (IQA). Biochem J 374: 639-646.
30. Sarno S, Reddy H, Meggio F, Ruzzene M, Davies SP, Donella-Deana A et al. (2001). Selectivity of 4,5,6,7-tetrabromobenzotriazole, an ATP site-directed inhibitor of protein kinase CK2 ('casein kinase-2'). FEBS Lett 496: 44-48.
31. Sarno S, Ruzzene M, Frascella P, Pagano MA, Meggio F, Zambon A et al. (2005). Development and exploitation of CK2 inhibitors. Mol Cell Biochem 274: 69-76.
32. Sarno S, Salvi M, Battistutta R, Zanotti G, Pinna LA. (2005a). Features and potentials of ATP-site directed CK2 inhibitors. Biochim Biophys Acta 1754: 263-270.
33. Sawicka M, Kalinowska M, Skierski J, Lewandowski W. (2004). A review of selected anti-tumour therapeutic agents and reasons for multidrug resistance occurrence. J Pharm Pharmacol 56: 1067-1081.
34. Seeber S, Issinger OG, Holm T, Kristensen LP, Guerra B. (2005). Validation of protein kinase CK2 as oncological target. Apoptosis 10: 875-885.
35. Seldin DC, Leder P. (1995). Casein kinase II alpha transgene-induced murine lymphoma: relation to theileriosis in cattle. Science 267: 894-897.
36. Szyszka R, Grankowski N, Felczak K, Shugar D. (1995). Halogenated benzimidazoles and benzotriazoles as selective inhibitors of protein kinases CK I and CK II from Saccharomyces cerevisiae and other sources. Biochem Biophys Res Commun 208: 418-424.
37. Tapia JC, Torres VA, Rodriguez DA, Leyton L, Quest AF. (2006). Casein kinase 2 (CK2) increases survivin expression via enhanced beta-catenin-T cell factor/lymphoid enhancer binding factor-dependent transcription. Proc Natl Acad Sci USA 103: 15079-15084.